Butros LJ, Bussel JB. Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis. J Pediatr Hematol Oncol. 2003 Aug. 25(8):660-4. [QxMD MEDLINE Link].
Fogarty PF, Segal JB. The epidemiology of immune thrombocytopenic purpura. Curr Opin Hematol. 2007 Sep. 14(5):515-9. [QxMD MEDLINE Link].
Nilsson T, Norberg B. Thrombocytopenia and pseudothrombocytopenia: a clinical and laboratory problem. Scand J Haematol. 1986 Oct. 37(4):341-6. [QxMD MEDLINE Link].
Jubelirer SJ, Harpold R. The role of the bone marrow examination in the diagnosis of immune thrombocytopenic purpura: case series and literature review. Clin Appl Thromb Hemost. 2002 Jan. 8(1):73-6. [QxMD MEDLINE Link].
Calpin C, Dick P, Poon A, Feldman W. Is bone marrow aspiration needed in acute childhood idiopathic thrombocytopenic purpura to rule out leukemia?. Arch Pediatr Adolesc Med. 1998 Apr. 152(4):345-7. [QxMD MEDLINE Link]. [Full Text].
Sandler SG, Tutuncuoglu SO. Immune thrombocytopenic purpura - current management practices. Expert Opin Pharmacother. 2004 Dec. 5(12):2515-27. [QxMD MEDLINE Link].
Tarantino MD, Buchanan GR. The pros and cons of drug therapy for immune thrombocytopenic purpura in children. Hematol Oncol Clin North Am. 2004 Dec. 18(6):1301-14, viii. [QxMD MEDLINE Link].
[Guideline] Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019 Dec 10. 3 (23):3829-3866. [QxMD MEDLINE Link]. [Full Text].
Mazzucconi MG, Fazi P, Bernasconi S, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood. 2007 Feb 15. 109(4):1401-7. [QxMD MEDLINE Link]. [Full Text].
Borst F, Keuning JJ, van Hulsteijn H, Sinnige H, Vreugdenhil G. High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults. Ann Hematol. 2004 Dec. 83(12):764-8. [QxMD MEDLINE Link].
Cheng Y, Wong RS, Soo YO, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003 Aug 28. 349(9):831-6. [QxMD MEDLINE Link]. [Full Text].
Imbach P, Barandun S, d'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981 Jun 6. 1(8232):1228-31. [QxMD MEDLINE Link].
Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev. 2007 Apr. 21(2 suppl 1):S9-56. [QxMD MEDLINE Link].
Sandler SG. Treating immune thrombocytopenic purpura and preventing Rh alloimmunization using intravenous rho (D) immune globulin. Transfus Med Rev. 2001 Jan. 15(1):67-76. [QxMD MEDLINE Link].
Sandler SG, Novak SC, Roland B. The cost of treating immune thrombocytopenic purpura using intravenous Rh immune globulin versus intravenous immune globulin. Am J Hematol. 2000 Mar. 63(3):156-8. [QxMD MEDLINE Link]. [Full Text].
Gaines AR. Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood. 2000 Apr 15. 95(8):2523-9. [QxMD MEDLINE Link]. [Full Text].
Chun NS, Savani B, Seder RH, Taplin ME. Acute renal failure after intravenous anti-D immune globulin in an adult with immune thrombocytopenic purpura. Am J Hematol. 2003 Dec. 74(4):276-9. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Rajasekhar A, Gernsheimer T, Stasi R, James AH. 2013 Clinical Practice Guide on Thrombocytopenia in Pregnancy. American Society of Hematology. Available at http://www.hematology.org/Clinicians/Guidelines-Quality/Quick-Reference.aspx. Accessed: July 20, 2023.
Gottlieb P, Axelsson O, Bakos O, Rastad J. Splenectomy during pregnancy: an option in the treatment of autoimmune thrombocytopenic purpura. Br J Obstet Gynaecol. 1999 Apr. 106(4):373-5. [QxMD MEDLINE Link].
Matzdorff A, Meyer O, Ostermann H, Kiefel V, Eberl W, Kühne T, et al. Immune Thrombocytopenia - Current Diagnostics and Therapy: Recommendations of a Joint Working Group of DGHO, ÖGHO, SGH, GPOH, and DGTI. Oncol Res Treat. 2018. 41 Suppl 5:1-30. [QxMD MEDLINE Link]. [Full Text].
Stasi R, Evangelista ML, Stipa E, et al. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost. 2008 Jan. 99(1):4-13. [QxMD MEDLINE Link]. [Full Text].
Audia S, Mahévas M, Samson M, Godeau B, Bonnotte B. Pathogenesis of immune thrombocytopenia. Autoimmun Rev. 2017 Jun. 16 (6):620-632. [QxMD MEDLINE Link].
Chan H, Moore JC, Finch CN, Warkentin TE, Kelton JG. The IgG subclasses of platelet-associated autoantibodies directed against platelet glycoproteins IIb/IIIa in patients with idiopathic thrombocytopenic purpura. Br J Haematol. 2003 Sep. 122(5):818-24. [QxMD MEDLINE Link].
Crow AR, Lazarus AH. Role of Fcgamma receptors in the pathogenesis and treatment of idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol. 2003 Dec. 25 suppl 1:S14-8. [QxMD MEDLINE Link].
Sandler SG. The spleen and splenectomy in immune (idiopathic) thrombocytopenic purpura. Semin Hematol. 2000 Jan. 37(1 suppl 1):10-2. [QxMD MEDLINE Link].
Malik A, Sayed AA, Han P, et al. The role of CD8+ T-cell clones in immune thrombocytopenia. Blood. 2023 May 18. 141 (20):2417-2429. [QxMD MEDLINE Link]. [Full Text].
Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost. 2006 Nov. 4(11):2377-83. [QxMD MEDLINE Link]. [Full Text].
Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood. 2014 Nov 20. 124(22):3308-15. [QxMD MEDLINE Link].
Danese MD, Lindquist K, Gleeson M, Deuson R, Mikhael J. Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura. Am J Hematol. 2009 Jul 16. [QxMD MEDLINE Link].
Medeiros D, Buchanan GR. Major hemorrhage in children with idiopathic thrombocytopenic purpura: immediate response to therapy and long-term outcome. J Pediatr. 1998 Sep. 133(3):334-9. [QxMD MEDLINE Link].
Arnold DM. Bleeding complications in immune thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2015 Dec 5. 2015 (1):237-42. [QxMD MEDLINE Link].
KUhne T, Imbach P, Bolton-Maggs PH, et al, for the Intercontinental Childhood ITP Study Group. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet. 2001 Dec 22-29. 358(9299):2122-5. [QxMD MEDLINE Link].
Michel M, Rauzy OB, Thoraval FR, et al. Characteristics and outcome of immune thrombocytopenia in elderly: results from a single center case-controlled study. Am J Hematol. 2011 Dec. 86(12):980-4. [QxMD MEDLINE Link].
Heitink-Pollé KM, Nijsten J, Boonacker CW, de Haas M, Bruin MC. Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis. Blood. 2014 Nov 20. 124(22):3295-307. [QxMD MEDLINE Link].
Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008 Feb 2. 371(9610):395-403. [QxMD MEDLINE Link].
Zheng T, Chunlei L, Zhen W, Ping L, Haitao Z, Weixin H, et al. Clinical-Pathological Features and Prognosis of Thrombotic Thrombocytopenic Purpura in Patients With Lupus Nephritis. Am J Med Sci. 2009 Sep 9. [QxMD MEDLINE Link].
Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009 Jun 25. 113 (26):6511-21. [QxMD MEDLINE Link]. [Full Text].
Perricone C, Ceccarelli F, Nesher G, Borella E, Odeh Q, Conti F, et al. Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases. Immunol Res. 2014 Dec. 60 (2-3):226-35. [QxMD MEDLINE Link].
Rajantie J, Zeller B, Treutiger I, Rosthöj S, NOPHO ITP working group and five national study groups. Vaccination associated thrombocytopenic purpura in children. Vaccine. 2007 Feb 26. 25 (10):1838-40. [QxMD MEDLINE Link].
Di Pietrantonj C, Rivetti A, Marchione P, Debalini MG, Demicheli V. Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database Syst Rev. 2021 Nov 22. 11 (11):CD004407. [QxMD MEDLINE Link]. [Full Text].
Lafaurie M, Lapeyre-Mestre M, Sailler L, Sommet A, Moulis G. Risk of Immune Thrombocytopenia After Influenza Vaccine. JAMA Intern Med. 2022 Apr 1. 182 (4):444-445. [QxMD MEDLINE Link]. [Full Text].
Bidari A, Asgarian S, Pour Mohammad A, Naderi D, Anaraki SR, Gholizadeh Mesgarha M, et al. Immune thrombocytopenic purpura secondary to COVID-19 vaccination: A systematic review. Eur J Haematol. 2023 Apr. 110 (4):335-353. [QxMD MEDLINE Link]. [Full Text].
Lee EJ, Beltrami-Moreira M, Al-Samkari H, Cuker A, DiRaimo J, Gernsheimer T, et al. SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP. Blood. 2022 Mar 10. 139 (10):1564-1574. [QxMD MEDLINE Link]. [Full Text].
Visentin GP, Liu CY. Drug-induced thrombocytopenia. Hematol Oncol Clin North Am. 2007 Aug. 21(4):685-96, vi. [QxMD MEDLINE Link]. [Full Text].
Reese JA, Li X, Hauben M, Aster RH, Bougie DW, Curtis BR. Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood. 2010 Sep 23. 116(12):2127-33. [QxMD MEDLINE Link].
[Guideline] Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019 Nov 26. 3 (22):3780-3817. [QxMD MEDLINE Link]. [Full Text].
Sundell IB, Koka PS. Thrombocytopenia in HIV infection: impairment of platelet formation and loss correlates with increased c-Mpl and ligand thrombopoietin expression. Curr HIV Res. 2006 Jan. 4(1):107-16. [QxMD MEDLINE Link].
Raife TJ, Olson JD, Lentz SR. Platelet antibody testing in idiopathic thrombocytopenic purpura. Blood. 1997 Feb 1. 89(3):1112-4. [QxMD MEDLINE Link]. [Full Text].
Emilia G, Luppi M, Zucchini P, et al. Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles. Blood. 2007 Dec 1. 110(12):3833-41. [QxMD MEDLINE Link]. [Full Text].
Franchini M, Cruciani M, Mengoli C, Pizzolo G, Veneri D. Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis. J Antimicrob Chemother. 2007 Aug. 60(2):237-46. [QxMD MEDLINE Link]. [Full Text].
Inaba T, Mizuno M, Take S, et al. Eradication of Helicobacter pylori increases platelet count in patients with idiopathic thrombocytopenic purpura in Japan. Eur J Clin Invest. 2005 Mar. 35(3):214-9. [QxMD MEDLINE Link].
Sato R, Murakami K, Watanabe K, et al. Effect of Helicobacter pylori eradication on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura. Arch Intern Med. 2004 Sep 27. 164(17):1904-7. [QxMD MEDLINE Link]. [Full Text].
Hwang JJ, Lee DH, Yoon H, Shin CM, Park YS, Kim N. The Effects of Helicobacter pylori Eradication Therapy for Chronic Idiopathic Thrombocytopenic Purpura. Gut Liver. 2015 Sep 9. [QxMD MEDLINE Link].
Ahn ER, Tiede MP, Jy W, et al. Platelet activation in Helicobacter pylori-associated idiopathic thrombocytopenic purpura: eradication reduces platelet activation but seldom improves platelet counts. Acta Haematol. 2006. 116(1):19-24. [QxMD MEDLINE Link].
Michel M, Cooper N, Jean C, Frissora C, Bussel JB. Does Helicobacter pylori initiate or perpetuate immune thrombocytopenic purpura?. Blood. 2004 Feb 1. 103(3):890-6. [QxMD MEDLINE Link]. [Full Text].
Lai SW, Lin HF, Lin CL, Liao KF. Immune thrombocytopenic purpura might be an early hematologic manifestation of undiagnosed human immunodeficiency virus infection. Intern Emerg Med. 2017 Mar. 12 (2):157-162. [QxMD MEDLINE Link].
[Guideline] Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011 Apr 21. 117 (16):4190-207. [QxMD MEDLINE Link]. [Full Text].
Li X, Zhu W, Bao J, Li J, Zhou Y. Efficacy and safety of cyclosporine-based regimens for primary immune thrombocytopenia: a systematic review and meta-analysis. J Int Med Res. 2023 Jan. 51 (1):3000605221149870. [QxMD MEDLINE Link]. [Full Text].
McMillan R, Bussel JB, George JN, Lalla D, Nichol JL. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol. 2008 Feb. 83(2):150-4. [QxMD MEDLINE Link].
Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002 Mar 28. 346(13):995-1008. [QxMD MEDLINE Link].
Bussel JB. Novel approaches to refractory immune thrombocytopenic purpura. Blood Rev. 2002 Mar. 16(1):31-6. [QxMD MEDLINE Link].
McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med. 1997 Feb 15. 126(4):307-14. [QxMD MEDLINE Link].
Godeau B, Durand JM, Roudot-Thoraval F, et al. Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases. Br J Haematol. 1997 May. 97(2):336-9. [QxMD MEDLINE Link].
Facon T, Caulier MT, Wattel E, et al. A randomized trial comparing vinblastine in slow infusion and by bolus i.v. injection in idiopathic thrombocytopenic purpura: a report on 42 patients. Br J Haematol. 1994 Mar. 86(3):678-80. [QxMD MEDLINE Link].
Emilia G, Morselli M, Luppi M, et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood. 2002 Feb 15. 99(4):1482-5. [QxMD MEDLINE Link]. [Full Text].
Chalmers S, Tarantino MD. Romiplostim as a treatment for immune thrombocytopenia: a review. J Blood Med. 2015. 6:37-44. [QxMD MEDLINE Link]. [Full Text].
Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010 Nov 11. 363(20):1889-99. [QxMD MEDLINE Link].
Bussel JB, Hsieh L, Buchanan GR, Stine K, Kalpatthi R, Gnarra DJ, et al. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP). Pediatr Blood Cancer. 2014 Oct 24. [QxMD MEDLINE Link].
Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, et al. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016 Jul 2. 388 (10039):45-54. [QxMD MEDLINE Link].
Michel M, Wasser J, Godeau B, Aledort L, Cooper N, Tomiyama Y, et al. Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥65 years with immune thrombocytopenia. Ann Hematol. 2015 Sep 4. [QxMD MEDLINE Link].
Cines DB, Gernsheimer T, Wasser J, Godeau B, Provan D, Lyons R, et al. Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim. Int J Hematol. 2015 Sep. 102 (3):259-70. [QxMD MEDLINE Link].
FDA expands use of Novartis drug Promacta® to include treatment of children ages 1 and older with chronic immune thrombocytopenia. Novartis. Available at https://www.novartis.com/news/media-releases/fda-expands-use-novartis-drug-promacta-include-treatment-children-ages-1-and-older-chronic-immune-thrombocytopenia. August 24, 2015; Accessed: July 20, 2023.
Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011 Jan 29. 377(9763):393-402. [QxMD MEDLINE Link].
Jurczak W, Chojnowski K, Mayer J, Krawczyk K, Jamieson BD, Tian W, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018 Nov. 183 (3):479-490. [QxMD MEDLINE Link]. [Full Text].
Al-Samkari H, Jiang D, Gernsheimer T, Liebman H, Lee S, Wojdyla M, et al. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study. Br J Haematol. 2022 May. 197 (3):359-366. [QxMD MEDLINE Link]. [Full Text].
Schultz CL, Mitra N, Schapira MM, Lambert MP. Influence of the American Society of Hematology guidelines on the management of newly diagnosed childhood immune thrombocytopenia. JAMA Pediatr. 2014 Oct. 168(10):e142214. [QxMD MEDLINE Link].
Roganovic J. Rituximab treatment in refractory idiopathic thrombocytopenic purpura in children. Eur J Pediatr. 2005 May. 164(5):334. [QxMD MEDLINE Link].
Taube T, Schmid H, Reinhard H, von Stackelberg A, Overberg US. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. Haematologica. 2005 Feb. 90(2):281-3. [QxMD MEDLINE Link]. [Full Text].
Cooper N, Evangelista ML, Amadori S, Stasi R. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?. Curr Opin Hematol. 2007 Nov. 14(6):642-6. [QxMD MEDLINE Link].
Gudbrandsdottir S, Birgens HS, Frederiksen H, Jensen BA, Jensen MK, Kjeldsen L, et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood. 2013 Mar 14. 121(11):1976-81. [QxMD MEDLINE Link].
Bussel JB, et al. Treatment of Primary Adult Chronic Immune Thrombocytopenia (CITP) with Fostamatinib, an Oral SYK Inhibitor: Results of Two Randomized, Placebo-Controlled Phase 3 Studies. Presented at the European Hematology Association 22nd Annual Congress. Madrid, Spain. 2017 Jun 24.
George JN. Management of immune thrombocytopenia--something old, something new. N Engl J Med. 2010 Nov 11. 363(20):1959-61. [QxMD MEDLINE Link].
Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017 May 25. 129 (21):2829-2835. [QxMD MEDLINE Link].
Khan LR, Nixon SJ. Laparoscopic splenectomy is a better treatment for adult ITP than steroids--it should be used earlier in patient management. Conclusions of a ten-year follow-up study. Surgeon. 2007 Feb. 5(1):3-4, 6-8. [QxMD MEDLINE Link].
Rescorla FJ, West KW, Engum SA, Grosfeld JL. Laparoscopic splenic procedures in children: experience in 231 children. Ann Surg. 2007 Oct. 246(4):683-7; discussion 687-8. [QxMD MEDLINE Link].
Mikhael J, Northridge K, Lindquist K, Kessler C, Deuson R, Danese M. Short-term and long-term failure of laparoscopic splenectomy in adult immune thrombocytopenic purpura patients: A systematic review. Am J Hematol. 2009 Jul 16. [QxMD MEDLINE Link].
Bell WR Jr. Role of splenectomy in immune (idiopathic) thrombocytopenic purpura. Blood Rev. 2002 Mar. 16(1):39-41. [QxMD MEDLINE Link].
Rodeghiero F, Frezzato M, Schiavotto C, Castaman G, Dini E. Fulminant sepsis in adults splenectomized for idiopathic thrombocytopenic purpura. Haematologica. 1992 May-Jun. 77(3):253-6. [QxMD MEDLINE Link].
Zarrabi MH, Rosner F. Serious infections in adults following splenectomy for trauma. Arch Intern Med. 1984 Jul. 144(7):1421-4. [QxMD MEDLINE Link].
Beattie JF, Michelson ML, Holman PJ. Acute babesiosis caused by Babesia divergens in a resident of Kentucky. N Engl J Med. 2002 Aug 29. 347(9):697-8. [QxMD MEDLINE Link].
Crary SE, Buchanan GR. Vascular complications after splenectomy for hematologic disorders. Blood. 2009 Oct 1. 114(14):2861-8. [QxMD MEDLINE Link].
Robinette CD, Fraumeni JF Jr. Splenectomy and subsequent mortality in veterans of the 1939-45 war. Lancet. 1977 Jul 16. 2(8029):127-9. [QxMD MEDLINE Link].
Purcell PL, Crary SE, Adix LM, Alder AC, Buchanan GR. Postsplenectomy vascular complications: Feasibility of studying patients with splenectomy following trauma. Am J Hematol. 2009 May. 84(5):316-7. [QxMD MEDLINE Link].
George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996 Jul 1. 88(1):3-40. [QxMD MEDLINE Link]. [Full Text].
Facon T, Caulier MT, Fenaux P, et al. Accessory spleen in recurrent chronic immune thrombocytopenic purpura. Am J Hematol. 1992 Nov. 41(3):184-9. [QxMD MEDLINE Link].
Woo JH, Park SH, Park YK, et al. Postsplenectomy recurrence of thrombocytopenia with an accessory spleen. Korean J Intern Med. 2004 Sep. 19(3):199-201. [QxMD MEDLINE Link]. [Full Text].
Dolan JP, Sheppard BC, DeLoughery TG. Splenectomy for immune thrombocytopenic purpura: surgery for the 21st century. Am J Hematol. 2008 Feb. 83(2):93-6. [QxMD MEDLINE Link].
Balagué C, Vela S, Targarona EM, et al. Predictive factors for successful laparoscopic splenectomy in immune thrombocytopenic purpura: study of clinical and laboratory data. Surg Endosc. 2006 Aug. 20(8):1208-13. [QxMD MEDLINE Link].
Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood. 2005 Oct 1. 106 (7):2244-51. [QxMD MEDLINE Link].
Blanchette VS, Carcao M. Childhood acute immune thrombocytopenic purpura: 20 years later. Semin Thromb Hemost. 2003 Dec. 29(6):605-17. [QxMD MEDLINE Link].